|
Report Date : |
13.11.2014 |
IDENTIFICATION DETAILS
|
Name : |
LABORATRIO MAVERN
LTD |
|
|
|
|
Registered Office : |
Alas Encinasi 1777, Loteo Vallegrande, Lampa -Santiago |
|
|
|
|
Country : |
Chile |
|
|
|
|
Date of Incorporation : |
01.01.1993 |
|
|
|
|
Legal Form : |
Sociedad Anónima |
|
|
|
|
Line of Business : |
Manufacturing of Pharmaceutical Products. |
|
|
|
|
No. of Employees : |
300 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 1, 2014
|
Country Name |
Previous Rating (31.03.2014) |
Current Rating (01.06.2014) |
|
Chile |
A2 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHILE - ECONOMIC OVERVIEW
Chile has a market-oriented
economy characterized by a high level of foreign trade and a reputation for
strong financial institutions and sound policy that have given it the strongest
sovereign bond rating in South America. Exports of goods and services account
for approximately one-third of GDP, with commodities making up some
three-quarters of total exports. Copper alone provides 19% of government
revenue. From 2003 through 2013, real growth averaged almost 5% per year,
despite the slight contraction in 2009 that resulted from the global financial
crisis. Chile deepened its longstanding commitment to trade liberalization with
the signing of a free trade agreement with the US, which took effect on 1
January 2004. Chile has 22 trade agreements covering 60 countries including
agreements with the European Union, Mercosur, China, India, South Korea, and
Mexico. Chile has joined the United States and nine other countries in
negotiating the Trans-Pacific-Partnership trade agreement. The Chilean
Government has generally followed a countercyclical fiscal policy, accumulating
surpluses in sovereign wealth funds during periods of high copper prices and
economic growth, and generally allowing deficit spending only during periods of
low copper prices and growth. As of 31 December 2012, those sovereign wealth
funds - kept mostly outside the country and separate from Central Bank reserves
- amounted to more than $20.9 billion. Chile used these funds to finance fiscal
stimulus packages during the 2009 economic downturn. In May 2010 Chile signed
the OECD Convention, becoming the first South American country to join the
OECD.
|
Source
: CIA |
|
Name |
LABORATRIO MAVERN LTD |
|
Address in the order: |
ALAS ENCINASI 1777, LOTEO VALLEGRANDE, LAMPA -SANTIAGO, CHILE. |
|
Legal Name: |
LABORATORIO MAVER S.A. |
|
Trade Name: |
Laboratorio Maver |
|
RUT: |
92121000-0 |
|
Date Created: |
1993 |
|
Date Incorporated: |
January 1, 1993 |
|
Legal Address: |
Calle Las Encinas 1777 Valle Grande Lampa, Lampa, Chile |
|
Operative Address: |
Calle Las Encinas 1777 Valle Grande Lampa, Lampa, Chile |
|
Telephone: |
(56-2) 2487 4100 |
|
Fax: |
(56-2) 2487 4292 |
|
Legal Form: |
Sociedad Anónima |
|
Email: |
|
|
Registered in: |
Chile |
|
Website: |
|
|
Manager: |
Fernando Albala |
|
Staff: |
300 |
|
Activity: |
Pharmaceutical Products Manufacturing |
|
Codes: |
2833 2834 2835 |
|
Name of the Bank: |
BANCO SANTANDER |
|
The company does not make its banking information public. |
|
|
In 1923, Mr. Elías Albala Franco was a member of one of the first generations
of pharmaceutical chemists to have graduated from the Universidad de Chile.
Just out of the university classroom, Mr. Elías Albala was to become the
founder of Laboratorios Maver
|
|
Maver Laboratories is a manufacturer of chemicals, specifically for the
pharmaceutical industry, producing drugs and medicines for headache, stomach
acid and other related ailments, including a select group of professionals
such as Dentists, Pharmaceutical Chemists and Engineers to supervise process
development for all products sold both in Chile and abroad. |
|
|
Products/Services description: |
MAVER OTC |
|
Brands: |
The company has more than 50 trademarks,
some of them are: |
|
Sales are: |
Wholesale |
|
Clients: |
Hospitals |
|
Suppliers: |
LIPOTEC S.A |
|
Operations area: |
National & International |
|
The company imports from |
India, Spain, Switzerland |
|
The company exports |
Worldwide |
|
The subject employs |
300 employees |
|
Payments: |
Regular |
|
Headquarters : |
Calle Las Encinas 1777 Valle Grande Lampa, Lampa, Chile |
|
Branches: |
The company does not have branches |
|
Business Overview: |
Companies in this industry manufacture and process pharmaceutical
products.
|
|
Listed at the stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders %: |
This is a private company fully owned by: |
|
Management: |
FERNANDO ALBALA CHAMUDES, PRESIDENT |
|
Related Companies: |
Perú |
|
This is aprivate company which
does not make its financial figures public. The following information is
estimated and could not be confirmed by the company. |
|
|
USD 2013 |
|
|
Gross Revenue |
50 000 000 |
|
Cash Flow |
Good |
|
Exportaciones en US$ |
|
|
Año |
Total |
|
2012 |
US$ 2,700,065 |
|
2011 |
US$ 2,373,129 |
|
2010 |
US$ 1,982,645 |
|
2009 |
US$ 1,981,463 |
|
Importaciones en US$ |
|
|
Año |
Total |
|
2012 |
US$ 6,669,350 |
|
2011 |
US$ 8,853,402 |
|
2010 |
US$ 8,734,713 |
|
2009 |
US$ 5,093,604 |
|
There are no legal/criminal connected to the subject. |
|
Maver is a company which is fully owned by
a single Chilean family. The company was created 87 years ago by a
pharmaceutical chemist, Elias Albala. |
|
Status |
ACTIVE |
|
Payments |
No Complaints |
|
Cash |
Good |
|
Indebtedness |
Controlled |
|
INTERVIEWEE |
Pedro |
|
POSITION |
Sales |
|
COMMENTS |
He confirmed address, staff, manager, activity and brands. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.48 |
|
|
1 |
Rs.97.92 |
|
Euro |
1 |
Rs.76.79 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
NIT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
|
-- |
NB |
New Business |
-- |
|
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.